Literature DB >> 32179411

PEST domain NOTCH mutations confer a poor relapse free survival in pediatric T-ALL: Data from a tertiary care centre in India.

Prateek Bhatia1, Sidharth Totadri2, Minu Singh3, Praveen Sharma4, Amita Trehan3, Deepak Bansal3, Richa Jain3, Neelam Varma4, Manupdesh S Sachdeva4, Nilamani Patra3.   

Abstract

A comprehensive genotype-phenotype analysis of pediatric T-ALL data was performed. 33 confirmed pediatric (≤12 y) T-ALL samples were evaluated for oncogenic transcripts: TLX-1, TLX-3, common fusion of STIL-TAL1, NOTCH1 mutations and copy number variations (CNVs). Mean WBC was 235.69 × 103/μL. TLX1 and TLX-3 overexpression detected in 1 (3%) and 7 (21%) patients and STIL-TAL1 in 8 (27%). NOTCH1 mutations were noted in 17 (52%), of which 12 (71%) in HD domain and 6 (35%) in PEST domain (including one case with mutations in all three domains). Commonest CNVs were CDKN2A (85%) and CDKN2B (75%). Relapse occurred in 8 (24%) patients. The median follow-up was 15 months (range: 0.5-36). Bulky liver (p = 0.025), day 35 marrow (p = 0.004) and NOTCH mutation (p = 0.046) were predictive of time to an event. RFS was significantly poor for cases with PEST Vs. HD domain mutations (50% Vs. 85%) (p = 0.0009). Though cases with PEST domain NOTCH mutations had poor RFS, the OS was not influenced by NOTCH mutation positivity.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NOTCH1; PEST domain; RFS; T-ALL

Mesh:

Substances:

Year:  2020        PMID: 32179411     DOI: 10.1016/j.bcmd.2020.102419

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  1 in total

1.  Clinico-Hematological Profile and Copy Number Abnormalities in a Cohort of STIL-TAL1 and NUP214-ABL1 Positive Pediatric T-Cell Acute Lymphoblastic Leukemia.

Authors:  Nilamani Patra; Minu Singh; Pankaj Sharma; Amita Trehan; Shano Naseem; Deepak Bansal; Prateek Bhatia
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-25       Impact factor: 0.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.